|
GB1039113A
(en)
|
1964-08-06 |
1966-08-17 |
Ucb Sa |
New n-substituted lactams
|
|
GB1309692A
(en)
|
1970-02-13 |
1973-03-14 |
Ucb Sa |
N-substituted lactams
|
|
IT1045043B
(it)
*
|
1975-08-13 |
1980-04-21 |
Isf Spa |
Derivati pirrolidinici
|
|
IT1075280B
(it)
*
|
1977-02-11 |
1985-04-22 |
Isf Spa |
Procedimento per la preparazione di derivati pirrolidinici
|
|
BE864269A
(fr)
*
|
1977-03-03 |
1978-06-16 |
Parke Davis & Co |
Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
|
|
ATE27T1
(de)
*
|
1978-05-08 |
1981-04-15 |
Ucb Sa |
Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
|
|
US4654370A
(en)
*
|
1979-03-12 |
1987-03-31 |
Abbott Laboratories |
Glyceryl valproates
|
|
US4372960A
(en)
*
|
1980-12-12 |
1983-02-08 |
Warner-Lambert Company |
Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
|
|
FR2515179A1
(fr)
*
|
1981-07-24 |
1983-04-29 |
Hoffmann La Roche |
Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
|
|
IL67623A
(en)
|
1983-01-05 |
1984-09-30 |
Teva Pharma |
1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
|
|
IL72381A
(en)
*
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
|
US4558070A
(en)
|
1983-10-26 |
1985-12-10 |
Abbott Laboratories |
Acid salts of valproic acid
|
|
GB8412358D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
GB8412357D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
US4668687A
(en)
*
|
1984-07-23 |
1987-05-26 |
Bristol-Myers Company |
Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
|
|
US4913906B1
(en)
*
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
|
JPS6222785A
(ja)
*
|
1985-07-23 |
1987-01-30 |
Sanwa Kagaku Kenkyusho:Kk |
新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
|
|
IT1190133B
(it)
*
|
1986-06-19 |
1988-02-10 |
Chiesi Farma Spa |
Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
|
|
DE3709230A1
(de)
*
|
1987-03-20 |
1988-10-06 |
Desitin Arzneimittel Gmbh |
Neues calciumsalz der valproinsaeure
|
|
JPS6422883A
(en)
*
|
1987-07-17 |
1989-01-25 |
Sanwa Kagaku Kenkyusho Co |
1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
|
|
EP0300111B1
(en)
*
|
1987-07-22 |
1991-10-16 |
Farvalsa AG |
A moisture stable solid valproic acid formulation and a method of preparing the same
|
|
HUT53607A
(en)
|
1989-01-17 |
1990-11-28 |
Hoffmann La Roche |
Process for production of derivatives of cyclohexan-acetamid
|
|
FR2643556B1
(fr)
|
1989-02-27 |
1993-03-05 |
Sanofi Sa |
Composition pharmaceutique a liberation prolongee d'acide valproique
|
|
IT1231477B
(it)
*
|
1989-07-12 |
1991-12-07 |
Sigma Tau Ind Farmaceuti |
(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
|
|
CA2067614C
(en)
*
|
1991-05-02 |
2002-07-30 |
Eiichi Otomo |
Agent for improving dementia
|
|
US5439930A
(en)
*
|
1992-04-14 |
1995-08-08 |
Russian-American Institute For New Drug Development |
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
|
|
US5440023A
(en)
|
1992-09-18 |
1995-08-08 |
Beckman Instruments, Inc. |
Method for making valproic acid derivatives
|
|
GB9319732D0
(en)
*
|
1993-09-24 |
1993-11-10 |
Ucb Sa |
Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
|
|
US5468733A
(en)
|
1993-09-30 |
1995-11-21 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5516759A
(en)
|
1994-12-08 |
1996-05-14 |
Tap Holdings Inc. |
LHRH antagonists having lactam groups at the N-terminus
|
|
IT1285801B1
(it)
|
1996-10-10 |
1998-06-24 |
Sigma Tau Ind Farmaceuti |
Procedimento migliorato per la preparazione dell'acido valproico
|
|
US6131106A
(en)
|
1998-01-30 |
2000-10-10 |
Sun Microsystems Inc |
System and method for floating-point computation for numbers in delimited floating point representation
|
|
US6620802B1
(en)
*
|
1999-11-23 |
2003-09-16 |
Corcept Therapeutics, Inc. |
Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
|
|
YU37602A
(sh)
|
1999-12-01 |
2005-07-19 |
Ucb S.A. |
Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
|
|
GB0004297D0
(en)
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
|
JPWO2002053153A1
(ja)
*
|
2000-12-28 |
2004-04-30 |
第一製薬株式会社 |
神経因性疼痛治療及び予防薬
|
|
US6610326B2
(en)
*
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
|
WO2002067931A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Johns Hopkins University |
Treatment of tics, tremors and related disorders
|
|
EP1395560A1
(en)
|
2001-05-23 |
2004-03-10 |
Ucb, S.A. |
2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
|
|
CA2457982C
(en)
*
|
2001-08-22 |
2009-11-03 |
Daiichi Pharmaceutical Co., Ltd. |
Use of nefiracetam for treating neurodegeneration
|
|
US7235579B2
(en)
|
2001-10-16 |
2007-06-26 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
|
US20040116506A1
(en)
*
|
2002-06-20 |
2004-06-17 |
Krusz John Claude |
Use of levetiracetam for treating or preventing acute headaches
|
|
US7557137B2
(en)
*
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
|
EP1625378A4
(en)
*
|
2002-12-03 |
2007-05-16 |
Ucb Sa |
METHOD OF IDENTIFYING AGENTS FOR THE TREATMENT OF CEREALS, NEUROLOGICAL DISEASES, ENDOCRINOPATHIES AND HORMONE DISEASES
|
|
US7090985B2
(en)
*
|
2002-12-03 |
2006-08-15 |
Ucb, S.A. |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
|
ITMI20030573A1
(it)
*
|
2003-03-24 |
2004-09-25 |
Nikem Research Srl |
Composti ad azione nootropica, loro preparazione,
|
|
TW200508197A
(en)
|
2003-03-31 |
2005-03-01 |
Ucb Sa |
Indolone-acetamide derivatives, processes for preparing them and their uses
|
|
JP2007513105A
(ja)
*
|
2003-12-02 |
2007-05-24 |
ユ セ ベ ソシエテ アノニム |
イミダゾール誘導体、その製法及び使用
|
|
US7618978B2
(en)
|
2004-04-22 |
2009-11-17 |
Eli Lilly And Company |
Amides as BACE inhibitors
|
|
CA2568700A1
(en)
|
2004-06-11 |
2005-12-22 |
Ucb, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
|
US20060063707A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
NZ556630A
(en)
*
|
2005-01-27 |
2010-12-24 |
Alembic Ltd |
Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
|
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
|
AU2006228947A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Mylan Pharmaceuticals Ulc |
Combined-step process for pharmaceutical compositions
|
|
EP1912966A2
(en)
|
2005-06-01 |
2008-04-23 |
Ucb, S.A. |
2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
|
|
EP1731149A1
(en)
*
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
|
GB0517740D0
(en)
|
2005-08-31 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
WO2007065595A2
(en)
|
2005-12-07 |
2007-06-14 |
Ucb Pharma, S.A. |
Xanthine derivatives, processes for preparing them and their uses
|
|
EP1991212A1
(en)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CA2651862A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US20080014271A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Ucb, S.A. |
Novel pharmaceutical compositions comprising levetiracetam
|
|
WO2008021666A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
|
WO2008095221A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of adhd
|
|
EP2152262A2
(en)
|
2007-04-27 |
2010-02-17 |
UCB Pharma, S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
|
KR20090031333A
(ko)
|
2007-09-21 |
2009-03-25 |
주식회사 엘지생명과학 |
신규한 베타-세크리타제 저해용 화합물
|
|
US20090176740A1
(en)
|
2007-11-30 |
2009-07-09 |
Phillips Ii Dauglas James |
Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
|
|
PT2273975E
(pt)
*
|
2008-03-03 |
2014-07-17 |
Ucb Pharma Sa |
Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
|
|
JP2010024156A
(ja)
|
2008-07-16 |
2010-02-04 |
Ucb Pharma Sa |
レベチラセタムを含む医薬組成物
|
|
MX2011001384A
(es)
|
2008-08-06 |
2011-09-27 |
Gosforth Ct Holdings Pty Ltd |
Composiciones y metodos para tratar trastornos psiquiatricos.
|
|
ES2865504T3
(es)
|
2008-10-16 |
2021-10-15 |
Univ Johns Hopkins |
Procedimientos y composiciones para la mejora de la función cognitiva
|
|
US9125898B2
(en)
*
|
2008-11-14 |
2015-09-08 |
Neurotune Ag |
Acetam derivatives for pain relief
|
|
PL2358360T3
(pl)
|
2008-11-18 |
2017-02-28 |
Ucb Biopharma Sprl |
Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
|
|
US20110275693A1
(en)
|
2009-01-29 |
2011-11-10 |
Ucb Pharma, S.A. |
Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
|
|
WO2010089372A1
(en)
|
2009-02-09 |
2010-08-12 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising brivaracetam
|
|
EP2461808A2
(en)
|
2009-08-07 |
2012-06-13 |
UCB Pharma S.A. |
Methods for enhancing the cognitive function
|